ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT04732065 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Midline Glioma (DMG)
Glioblastoma
Recurrent Ependymoma
Recurrent Malignant Central Nervous System Neoplasm
Spinal Cord Glioma
World Health Organization (WHO) Grade III Glioma
CNS Tumor
Central Nervous System Tumor

Interventions

DRUG: ONC206
RADIATION: Standard of Care Radiation Therapy
PROCEDURE: Optional Proton (1H) MR spectroscopy (MRS)

Sponsor

Sabine Mueller, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]